pharmaphorum

SEPTEMBER 27, 2022

Seagen’s deal is another endorsement of Lava’s Gammabody platform, which creates drug candidates that target immune cells known as gamma delta or V?9V?2 It comes after Johnson & Johnson’s Janssen Biotech division signed up to access the bispecific antibody technology in 2020, without revealing any financial details.

Immunization 111

Immunization Immunity 111

European Pharmaceutical Review

AUGUST 2, 2023

This is an additional ingredient designed to trigger a stronger immune response. The vaccine demonstrated a strong immune response in the trial. In a clinical trial, this vaccine was shown to faciliate a strong immune response against the Omicron BA.1 1 variant, in addition to the original 2020 strain.

Vaccines 98

Vaccines Immunity Immunization 98

pharmaphorum

DECEMBER 22, 2020

GSK also announced a deal with Sosei Heptares , based in Tokyo and Cambridge, UK, to discover and develop a small molecule target for inflammatory bowel disease and other gastrointestinal immune disorders. The post GSK ends 2020 with multi-million dollar deal frenzy to boost R&D appeared first on.

Immunity 52

Immunity Immunization 52

Pharmaceutical Business Review

APRIL 7, 2025

In June 2020, the antibody gained approval from the US regulator for treating adults with aquaporin-4 immunoglobulin G positive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD). . Time to first treated and adjudicated IgG4-RD flare was the trials primary endpoint.

Immunization 52

Immunization Immunity 52

pharmaphorum

JULY 13, 2022

Genentech has been looking at the platform since 2020 under the terms of a deal worth up to $1.7 Bicycle’s immuno-oncology pipeline is headed by BT7480, a tumour-targeted immune cell agonist (TICA) that binds to Nectin-4 on cancer cells and stimulates CD137 on immune cells, driving an immune response.

Immunity 105

Immunity Immunization Compounding 105

European Pharmaceutical Review

JULY 13, 2023

The field of immunotherapy is constantly evolving with the ultimate goal to develop new treatments that help the body’s immune system fight cancer. Immune cells, such as T cells and natural killer (NK) cells, have the inherent ability to combat diseases, including cancer, but are often inhibited by the body’s own suppressive mechanisms.

Immunity 98

Immunity Immunization Hospitals 98

Express Pharma

OCTOBER 16, 2024

Ophelia Chan, Business Fundamentals Senior Analyst at GlobalData, comments, “The COVID-19 pandemic highlighted the key advantages of mRNA technology in vaccine development, including rapid production, precise immune targeting, and streamlined manufacturing- factors that drove the success of mRNA-based COVID-19 vaccines.” billion in July 2024.

Vaccines 104

Vaccines Immunization Immunity Diabetes 104

pharmaphorum

JUNE 16, 2022

It also probably marks the end of the road for crenezumab, which Roche’s Genentech subsidiary licensed from AC Immune in 2006 in a deal initially valued at $300 million. Before the end of the year, Roche should report results from two phase 3 studies in early-stage patients.

Immunization 111

Immunization Immunity 111

Pharmaceutical Technology

NOVEMBER 25, 2022

The platform could potentially forecast and design several tumour vaccines that can trigger certain immune responses to fight tumours. Additionally, the platform could produce preclinical tumour vaccine candidate compounds with strong immune activity by incorporating algorithmic feedback to streamline activity and efficacy.

Vaccines 98

Vaccines Immunity Immunization Process Improvement 98

pharmaphorum

OCTOBER 5, 2022

The disease – commonly known as the clap – was diagnosed in 82 million people in 2020 according to World Health organisation (WHO) estimates and ranks high among the agency’s infectious diseases of greatest concerns as it is rapidly becoming resistant to antimicrobial medicines. Dutch biotech Intravacc has been given a $14.6

Vaccines 98

Vaccines Immunity Immunization 98

pharmaphorum

JANUARY 27, 2022

Lab studies have suggested that this type of stimulation can alter immune cells made in the spleen switching them from a pro-inflammation to an anti-inflammation state. Galvani is using its device to stimulate the splenic nerve, which sends signals to the spleen.

Immunization 110

Immunization Immunity 110

pharmaphorum

JUNE 21, 2021

Pre-pandemic, the plan was to start both a phase 2 and phase 3 of BNT111 in 2020, but with the Pfizer-partnered COVID-19 shot consuming its attention, timelines have slipped back.

Vaccines 145

Vaccines Immunity Immunization 145

pharmaphorum

AUGUST 17, 2021

They discuss the publicly-listed biotech’s pipeline projects and focus on the BIG (brain-immune-gut) axis as well as PureTech’s interest in digital therapeutics. Prior to this, he founded pharmaphorum in 2009, which was acquired by Healthware Group in June 2020.

Communication 111

Communication Immunization Immunity 111

pharmaphorum

NOVEMBER 15, 2022

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-ranging push across cancer, immune-mediated, and neurological diseases.

Immunization 105

Immunization Immunity Compounding 105

pharmaphorum

FEBRUARY 9, 2022

Closely related to this is the fact that global spending on oncology drugs reached $164 billion in 2020, with drug sales growing at a compound annual growth rate of 14.3% Using a vaccine to utilise the patient’s own immune system to fight cancer is particularly attractive because of the targeted approach made possible by this technology.

Vaccines 134

Vaccines Immunization Immunity Labelling 134

pharmaphorum

JANUARY 13, 2021

The Series B fundraiser follows the FDA’s decision to grant Breakthrough Therapy designation last month for a combination of its lead immune-oncology therapies IO102 and IO103, with anti-PD-1 monoclonal antibodies for patients with metastatic melanoma.

Vaccines 95

Vaccines Immunization Immunity Compounding 95

pharmaphorum

MARCH 10, 2022

Scenic’s lead development project is in immuno-oncology, targeting QPTCL, an enzyme present in cancer cells that modifies the CD47 immune checkpoint, which protects tumour cells from being attacked and eaten by immune cells.

Immunization 98

Immunization Immunity 98

European Pharmaceutical Review

FEBRUARY 1, 2024

Epcoritamab is designed to simultaneously attach to two different cells, one immune T cell and one cancerous lymphoma cell, bringing them together. In this way, the immune T cell is activated to eliminate the cancerous lymphoma cell, based on a EBioMedicine paper published in 2020.

Immunization 98

Immunization Immunity Hospitals 98

Pharmaceutical Technology

APRIL 11, 2023

Dubbed Project Next Gen, the new effort will follow an approach similar to that of Operation Warp Speed, which developed and delivered vaccines to Covid-19 patients in 2020 by forming private-public partnerships for the rapid development of new vaccines.

Vaccines 105

Vaccines Immunization Immunity 105

European Pharmaceutical Review

AUGUST 16, 2022

HCC accounted for more approximately 85 percent of the 900,000 new liver cancer cases in 2020, according to the Globocan 2020 database. . receptors on macrophages, helping the body’s immune cells to detect and fight tumours. Hepatocellular carcinoma, or HCC, is the sixth most common type of cancer worldwide. About tislelizumab.

Labelling 98

Labelling Immunity Immunization 98

pharmaphorum

AUGUST 2, 2022

The collaboration adds to an earlier drug discovery agreement in the area of immunology and inflammation which dates back to June 2020, suggesting AbbVie likes what it has seen in the earlier alliance. The new deal comes with a signing fee of $40 million, another $40 million in milestones that could accrue in the next few years, and up to $1.2

Immunization 97

Immunization Immunity 97

European Pharmaceutical Review

JULY 11, 2022

CPI has been working together with these partners since mid-2020 to develop this type of vaccine to ensure it can be manufactured in the quantities and price range required to have a real impact everywhere,” noted Kris Wadrop, CPI General Manager and the Project Lead. 2 is the virus that causes COVID-19.). The novel vaccine?is

Vaccines 98

Vaccines Immunization Immunity 98

pharmaphorum

FEBRUARY 24, 2021

Back in 2020 savings from biosimilars were forecasted to really get going in that year and through to 2022. Throughout 2020 details emerged about a new network that will see health economics become part of informes de posicionamiento terapéutico (therapeutic positioning reports, IPTs). Revalmed was formally launched in November 2020.

Biosimilars 100

Biosimilars Immunity Immunization 100

pharmaphorum

JULY 20, 2022

VB-111 is delivered using an adenoviral vector via intravenous infusion, and is designed to mount a two-pronged attack on tumours, stimulating an immune response against malignant cells whilst also cutting off the blood supply to the cancer.

Chemotherapy 98

Chemotherapy Immunization Immunity 98

pharmaphorum

DECEMBER 22, 2020

There is no evidence to suggest the new strain causes more serious illness, but it does show variations in the “spike” protein that the virus uses to infect cells – the same protein that the Pfizer/BioNTech shot uses to confer immunity. Feature image copyright BioNTech SE 2020, all rights reserved.

Vaccines 81

Vaccines Immunization Immunity 81

pharmaphorum

OCTOBER 27, 2022

The Swiss biotech is seeking a priority review for vamorolone, which was licensed from US biotech ReveraGen BioPharma in 2020 after Santhera its former DMD therapy candidate idebenone failed clinical testing and was abandoned.

Immunity 98

Immunity Immunization 98

pharmaphorum

SEPTEMBER 15, 2020

Humanigen is hoping for emergency use authorisation in the US for an antibody to treat severe COVID-19 before the end of 2020, and has teamed up with Swiss contract manufacturer Lonza to make sure it can meet demand. Humanigen now expects to complete enrolment of the 300 subjects this month with topline results due in the fourth quarter.

Mayo Clinic 97

Mayo Clinic Immunization Immunity Hospitals 97

pharmaphorum

MARCH 24, 2022

There’s a rich history of finding useful medicines from fungi, from the antibiotic penicillin to immune suppressant cyclosporine and cholesterol drug lovastatin. The examples remain few and far between, however, as in recent decades the pharma industry has turned its attention to synthetic molecules and biologics like antibodies. .”

Compounding 105

Compounding Immunity Immunization Drug Development 105

pharmaphorum

JANUARY 7, 2022

In 2020, the company claimed a first by becoming the first to take an AI-designed drug into the human testing stage – a candidate for obsessive-compulsive disorder partnered with Sumitomo Dainippon Pharma (DSP).

Immunity 110

Immunity Immunization 110

pharmaphorum

SEPTEMBER 14, 2020

— Matt Hancock (@MattHancock) September 12, 2020. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body. This pause shows we will always put safety first.

Vaccines 104

Vaccines Immunity Immunization 104

European Pharmaceutical Review

MAY 4, 2023

Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. 4 BsMAb amivantamab was designed to enhance adherence of tumour cells to macrophages and natural killer cells, to improve immune-cell mediated killing of cancer cells. 2020; 19(10): 2044–56.

Immunization 98

Immunization Immunity Chemotherapy 98

pharmaphorum

DECEMBER 22, 2021

CFI regulates the activity of the complement immune system which is over-activated in GA. It’s worth noting also that Novartis already has a position in GA, which derives from its $280 million takeover of US startup Vedere Bio in 2020, although that programme is in preclinical development. It has been fast-tracked by the FDA.

Immunity 105

Immunity Immunization 105

pharmaphorum

NOVEMBER 23, 2021

With prospects for idebenone looking shaky, Santhera snapped up vamorolone from US biotech ReveraGen BioPharma in August 2020 , claiming worldwide rights to the nonhormonal steroid modulator in DMD and all other indications.

Immunity 104

Immunity Immunization 104

Pharmaceutical Technology

AUGUST 15, 2022

MHRA chief executive Dr June Raine said: “I am pleased to announce the approval of the Moderna bivalent booster vaccine, which was found in the clinical trial to provide a strong immune response against the Omicron BA.1 1 variant as well as the original 2020 strain.”.

Vaccines 85

Vaccines Immunization Immunity 85

Pharmacy Times

OCTOBER 21, 2022

Researchers suggest that winter 2020 to 2021 public health interventions lowered natural immunity in children and put them at greater risk of respiratory infection after restrictions were lifted.

Immunity 40

Immunity Immunization 40

Pharmaceutical Technology

JUNE 29, 2022

It merges a glycoprotein E antigen and an adjuvant system, AS01B, to induce a VZV-specific immune response that can aid in overcoming VZV immunity decline as people age. A non-live, recombinant subunit adjuvanted vaccine, Shingrix is administered intramuscularly in two doses.

Vaccines 64

Vaccines Immunity Immunization 64

pharmaphorum

AUGUST 17, 2020

BMS is best known as an early pioneer of checkpoint inhibitor therapies, which work by flipping a biochemical switch on tumour cells that suddenly makes them visible to the immune system, allowing T-cells to mount an attack.

Immunity 59

Immunity Immunization 59